바이오시뮬레이션 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 용도별, 치료 영역별, 제공 모델별, 가격결정 모델별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Biosimulation Market Summary

The global biosimulation market size was valued at USD 4.1 billion in 2025 and is projected to grow from USD 4.8 billion in 2026 to USD 14.8 billion by 2033, at a CAGR of 17.3% from 2026 to 2033. The market in North America dominated with a revenue share of 44.2% in 2025.

This growth is driven by the increasing incidence of drug relapse cases due to drug resistance in diseases such as cancer, tuberculosis, and other bacterial infections. These trends are key drivers of market growth, underscoring the critical need to integrate biosimulation into the early development of a new generation of drugs. In addition, the rising demand for biosimulation tools among researchers, fueled by technological advancements and software upgrades, is expected to further enhance market growth.

Global Biosimulation Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global biosimulation market report based on product, application, therapeutic area, deployment model, pricing model, end use, and region.

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Software
  • Molecular Modeling & Simulation Software
  • Docking, molecular dynamics, QSAR
  • Small Molecules
  • Biologics
  • In-silico ADME (ChemAxon-type tools)
  • Large Pharma (Top ~30)
  • Mid Pharma (~30-300)
  • Emerging / Long-tail Pharma & Biotech
  • Physicochemical property prediction (logP, pKa, solubility, permeability)
  • Clinical Trial Design Software
  • Clinical trial simulation
  • Adaptive design
  • Virtual patients
  • Dose optimization
  • MIDD-linked applications
  • PK/PD Modeling and Simulation Software
  • Software
  • Compartmental modeling
  • Population PK/PD (Pop PK/PD)
  • Non-compartmental analysis (NCA)
  • Dose-response, bioequivalence
  • Customer
  • Large Pharma (Top ~30)
  • Mid Pharma (~30-300)
  • Emerging / Long-tail Pharma & Biotech
  • Pbpk Modeling and Simulation Software
  • ADME (mechanistic)
  • DDI modeling
  • FIH dose prediction
  • Special populations
  • Toxicity Prediction Software
  • Hepatotoxicity, cardiotoxicity, genotoxicity
  • QSAR, mechanistic, AI/ML models
  • ADME-linked toxicity
  • QSP / Systems Biology Software
  • Software
  • Mechanistic disease modeling
  • Multi-scale simulation
  • Integration with PBPK
  • Customer
  • Large Pharma (Top ~30)
  • Mid Pharma (~30-300)
  • Emerging / Long-tail Pharma & Biotech
  • Other Software
  • AI-driven platforms
  • RWD-integrated tools
• Services
  • Contract Services
  • Services
  • PK/PD services
  • Pop PK/PD
  • NCA
  • Compartmental
  • PBPK services
  • ADME
  • DDI
  • Special populations
  • Customer
  • Large Pharma (Top ~30)
  • Mid Pharma (~30-300)
  • Emerging / Long-tail Pharma & Biotech
  • Consulting
  • Large Pharma (Top ~30)
  • Mid Pharma (~30-300)
  • Emerging / Long-tail Pharma & Biotech
  • Implementation, Training & Support
  • Service
  • Deployment
  • Integration
  • Training
  • Customer
  • Large Pharma (Top ~30)
  • Mid Pharma (~30-300)
  • Emerging / Long-tail Pharma & Biotech
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Drug Discovery & Development
• Disease Modeling
• Other (Precision Medicine, Toxicology, etc., etc.)
• Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
• Oncology
• Cardiovascular Disease
• Infectious Disease
• Neurological Disorders
• Others
• Deployment Model Outlook (Revenue, USD Million, 2021 - 2033)
• Cloud-based
• On-premise
• Hybrid Model
• Pricing Model Outlook (Revenue, USD Million, 2021 - 2033)
• License-based Model
• Subscription-based Model
• Service-based Model
• Pay Per Use Model
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Life Sciences Companies
  • Pharmaceutical Companies
  • Biopharma Companies
  • Medical Device Companies
  • CROs/CDMOs
• Academic Research Institutions
• Others (Regulatory Authorities, etc.)
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Product Segment
  • 1.2.2. Application Segment
  • 1.2.3. Therapeutic Area Segment
  • 1.2.4. Deployment Model Segment
  • 1.2.5. Pricing Model Segment
  • 1.2.6. End Use Segment
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Total Market: CAGR Calculation
• 1.10. Objectives
  • 1.10.1. Objective 1
  • 1.10.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. Biosimulation Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising adoption of Model-Informed Drug Development
    • 3.2.1.2. Growing demand for personalized medicine
    • 3.2.1.3. Expansion of pharmaceutical and biotechnology R&D investments
    • 3.2.1.4. Increasing complexity of drug pipelines
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost associated with biosimulation technology and software
    • 3.2.2.2. Stringent regulatory requirements
  • 3.2.3. Case study Insights
  • 3.2.4. Emerging Technologies
• 3.3. Biosimulation Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
    • 3.3.2.4. Environmental Landscape
    • 3.3.2.5. Legal Landscape
    • 3.3.2.6. Social Landscape

Chapter 4. Bio simulation Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global bio simulation Market Product Movement Analysis
• 4.3. Global Biosimulation Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 4.4. Software
  • 4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.2. Molecular Modeling & Simulation Software
    • 4.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.2.2. Docking, molecular dynamics, QSAR
      • 4.4.2.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.2.2. Small Molecules
        • 4.4.2.2.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.2.3. Biologics
        • 4.4.2.2.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.2.3. In-silico ADME (e.g., ChemAxon-type tools)
      • 4.4.2.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.3.2. Large Pharma (Top ~30)
        • 4.4.2.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.3.3. Mid Pharma (~30-300)
        • 4.4.2.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.3.4. Emerging / Long-tail Pharma & Biotech
        • 4.4.2.3.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.2.4. Physicochemical property prediction (logP, pKa, solubility, permeability)
  • 4.4.3. Clinical Trial Design Software
    • 4.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.3.2. Clinical trial simulation
      • 4.4.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.3.3. Adaptive design
      • 4.4.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.3.4. Virtual patients
      • 4.4.3.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.3.5. Dose optimization
      • 4.4.3.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.3.6. MIDD-linked applications
      • 4.4.3.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.4. PK/PD Modeling and Simulation Software
    • 4.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.4.2. Software
      • 4.4.4.2.1. Compartmental modeling
        • 4.4.4.2.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.4.2.2. Population PK/PD (Pop PK/PD)
        • 4.4.4.2.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.4.2.3. Non-compartmental analysis (NCA)
        • 4.4.4.2.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.4.2.4. Dose-response, bioequivalence
        • 4.4.4.2.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.4.3. Customer
      • 4.4.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.4.3.2. Large Pharma (Top ~30)
        • 4.4.4.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.4.3.3. Mid Pharma (~30-300)
        • 4.4.4.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.4.3.4. Emerging / Long-tail Pharma & Biotech
        • 4.4.4.3.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.5. Pbpk Modeling and Simulation Software
    • 4.4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.5.2. ADME (mechanistic)
      • 4.4.5.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.5.3. DDI modeling
      • 4.4.5.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.5.4. FIH dose prediction
      • 4.4.5.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.5.5. Special populations
      • 4.4.5.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.6. Toxicity Prediction Software
    • 4.4.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.6.2. Hepatotoxicity, cardiotoxicity, genotoxicity
      • 4.4.6.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.6.3. QSAR, mechanistic, AI/ML models
      • 4.4.6.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.6.4. ADME-linked toxicity
      • 4.4.6.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.7. QSP / Systems Biology Software
    • 4.4.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.7.2. Software
      • 4.4.7.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.7.2.2. Mechanistic disease modeling
        • 4.4.7.2.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.7.2.3. Multi-scale simulation
        • 4.4.7.2.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.7.2.4. Integration with PBPK
        • 4.4.7.2.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.7.3. Customer
      • 4.4.7.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.7.3.2. Large Pharma (Top ~30)
        • 4.4.7.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.7.3.3. Mid Pharma (~30-300)
        • 4.4.7.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.7.3.4. Emerging / Long-tail Pharma & Biotech
        • 4.4.7.3.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.8. Other Software
    • 4.4.8.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.8.2. AI-driven platforms
      • 4.4.8.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.8.3. RWD-integrated tools
      • 4.4.8.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 4.5. Services
  • 4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.5.2. Contract Services
    • 4.5.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.5.2.2. Services
      • 4.5.2.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.5.2.2.2. PK/PD services
        • 4.5.2.2.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
          • 4.5.2.2.2.1.1. Pop PK/PD Services
            • 4.5.2.2.2.1.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
          • 4.5.2.2.2.1.2. NCA
            • 4.5.2.2.2.1.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
          • 4.5.2.2.2.1.3. Compartmental
            • 4.5.2.2.2.1.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
          • 4.5.2.2.2.1.4. PBPK Services
            • 4.5.2.2.2.1.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
            • 4.5.2.2.2.1.4.2. ADME
          • 4.5.2.2.2.1.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
            • 4.5.2.2.2.1.4.3. DDI
          • 4.5.2.2.2.1.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
            • 4.5.2.2.2.1.4.4. Special populations
          • 4.5.2.2.2.1.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.5.2.3. Customer
      • 4.5.2.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.5.2.3.2. Large Pharma (Top ~30)
        • 4.5.2.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.5.2.3.3. Mid Pharma (~30-300)
        • 4.5.2.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.5.2.3.4. Emerging / Long-tail Pharma & Biotech
        • 4.5.2.3.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.5.3. Consulting
    • 4.5.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.5.3.2. Large Pharma (Top ~30)
      • 4.5.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.5.3.2.2. Mid Pharma (~30-300)
      • 4.5.3.2.3. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.5.3.2.4. Emerging / Long-tail Pharma & Biotech
        • 4.5.3.2.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.5.4. Implementation, Training & Support
    • 4.5.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.5.4.2. Service
      • 4.5.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.5.4.2.2. Deployment
        • 4.5.4.2.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.5.4.2.3. Integration
        • 4.5.4.2.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.5.4.2.4. Training
        • 4.5.4.2.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.5.4.3. Customer
      • 4.5.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.5.4.3.2. Large Pharma (Top ~30)
        • 4.5.4.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.5.4.3.3. Mid Pharma (~30-300)
        • 4.5.4.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.5.4.3.4. Emerging / Long-tail Pharma & Biotech
        • 4.5.4.3.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Biosimulation Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Biosimulation Market Application Movement Analysis
• 5.3. Global Biosimulation Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 5.4. Drug Discovery & Development
  • 5.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 5.5. Disease Modeling
  • 5.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 5.6. Other (Precision Medicine, Toxicology, etc., etc.)
  • 5.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Biosimulation Market: Therapeutic Area Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Biosimulation Market Therapeutic Area Movement Analysis
• 6.3. Global Biosimulation Market Size & Trend Analysis, by Therapeutic Area, 2021 to 2033 (USD Million)
• 6.4. Oncology
  • 6.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 6.5. Cardiovascular Disease
  • 6.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 6.6. Infectious Disease
  • 6.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 6.7. Neurological Disorders
  • 6.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 6.8. Others
  • 6.8.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Biosimulation Market: Deployment Model Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Biosimulation Market Deployment Model Movement Analysis
• 7.3. Global Biosimulation Market Size & Trend Analysis, by Deployment Model, 2021 to 2033 (USD Million)
• 7.4. Cloud-based
  • 7.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 7.5. On-premises
  • 7.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 7.6. Hybrid Model
  • 7.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Biosimulation Market: Pricing Model Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. Global Biosimulation Market Pricing Model Movement Analysis
• 8.3. Global Biosimulation Market Size & Trend Analysis, by Pricing Model, 2021 to 2033 (USD Million)
• 8.4. License-based Model
  • 8.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 8.5. Subscription-based Model
  • 8.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 8.6. Service-based Model
  • 8.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 8.7. Pay Per Use Model
  • 8.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Biosimulation Market: End Use Estimates & Trend Analysis

• 9.1. Segment Dashboard
• 9.2. Global Biosimulation Market End Use Movement Analysis
• 9.3. Global Biosimulation Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 9.4. Life Science Companies
  • 9.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.2. Pharmaceutical Companies
    • 9.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.3. Biopharma Companies
    • 9.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.4. Medical Device Companies
    • 9.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.5. CROs/CDMOs
    • 9.4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 9.5. Academic Research Institutions
  • 9.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 9.6. Others (Regulatory Authorities, etc.)
  • 9.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 10. Biosimulation Market: Regional Estimates & Trend Analysis

• 10.1. Regional Market Share Analysis, 2025 & 2033
• 10.2. Regional Market Dashboard
• 10.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
• 10.4. North America
  • 10.4.1. U.S.
    • 10.4.1.1. Key country dynamics
    • 10.4.1.2. Regulatory framework
    • 10.4.1.3. Competitive scenario
    • 10.4.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.4.2. Canada
    • 10.4.2.1. Key country dynamics
    • 10.4.2.2. Regulatory framework
    • 10.4.2.3. Competitive scenario
    • 10.4.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.4.3. Mexico
    • 10.4.3.1. Key country dynamics
    • 10.4.3.2. Regulatory framework
    • 10.4.3.3. Competitive scenario
    • 10.4.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 10.5. Europe
  • 10.5.1. UK
    • 10.5.1.1. Key country dynamics
    • 10.5.1.2. Regulatory framework
    • 10.5.1.3. Competitive scenario
    • 10.5.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.5.2. Germany
    • 10.5.2.1. Key country dynamics
    • 10.5.2.2. Regulatory framework
    • 10.5.2.3. Competitive scenario
    • 10.5.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.5.3. France
    • 10.5.3.1. Key country dynamics
    • 10.5.3.2. Regulatory framework
    • 10.5.3.3. Competitive scenario
    • 10.5.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.5.4. Italy
    • 10.5.4.1. Key country dynamics
    • 10.5.4.2. Regulatory framework
    • 10.5.4.3. Competitive scenario
    • 10.5.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.5.5. Spain
    • 10.5.5.1. Key country dynamics
    • 10.5.5.2. Regulatory framework
    • 10.5.5.3. Competitive scenario
    • 10.5.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.5.6. Norway
    • 10.5.6.1. Key country dynamics
    • 10.5.6.2. Regulatory framework
    • 10.5.6.3. Competitive scenario
    • 10.5.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.5.7. Sweden
    • 10.5.7.1. Key country dynamics
    • 10.5.7.2. Regulatory framework
    • 10.5.7.3. Competitive scenario
    • 10.5.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.5.8. Denmark
    • 10.5.8.1. Key country dynamics
    • 10.5.8.2. Regulatory framework
    • 10.5.8.3. Competitive scenario
    • 10.5.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 10.6. Asia Pacific
  • 10.6.1. Japan
    • 10.6.1.1. Key country dynamics
    • 10.6.1.2. Regulatory framework
    • 10.6.1.3. Competitive scenario
    • 10.6.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.6.2. China
    • 10.6.2.1. Key country dynamics
    • 10.6.2.2. Regulatory framework
    • 10.6.2.3. Competitive scenario
    • 10.6.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.6.3. India
    • 10.6.3.1. Key country dynamics
    • 10.6.3.2. Regulatory framework
    • 10.6.3.3. Competitive scenario
    • 10.6.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.6.4. Australia
    • 10.6.4.1. Key country dynamics
    • 10.6.4.2. Regulatory framework
    • 10.6.4.3. Competitive scenario
    • 10.6.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.6.5. South Korea
    • 10.6.5.1. Key country dynamics
    • 10.6.5.2. Regulatory framework
    • 10.6.5.3. Competitive scenario
    • 10.6.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.6.6. Thailand
    • 10.6.6.1. Key country dynamics
    • 10.6.6.2. Regulatory framework
    • 10.6.6.3. Competitive scenario
    • 10.6.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 10.7. Latin America
  • 10.7.1. Brazil
    • 10.7.1.1. Key country dynamics
    • 10.7.1.2. Regulatory framework
    • 10.7.1.3. Competitive scenario
    • 10.7.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.7.2. Argentina
    • 10.7.2.1. Key country dynamics
    • 10.7.2.2. Regulatory framework
    • 10.7.2.3. Competitive scenario
    • 10.7.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 10.8. MEA
  • 10.8.1. South Africa
    • 10.8.1.1. Key country dynamics
    • 10.8.1.2. Regulatory framework
    • 10.8.1.3. Competitive scenario
    • 10.8.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.8.2. Saudi Arabia
    • 10.8.2.1. Key country dynamics
    • 10.8.2.2. Regulatory framework
    • 10.8.2.3. Competitive scenario
    • 10.8.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.8.3. UAE
    • 10.8.3.1. Key country dynamics
    • 10.8.3.2. Regulatory framework
    • 10.8.3.3. Competitive scenario
    • 10.8.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.8.4. Kuwait
    • 10.8.4.1. Key country dynamics
    • 10.8.4.2. Regulatory framework
    • 10.8.4.3. Competitive scenario
    • 10.8.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 11. Competitive Landscape

• 11.1. Company/Competition Categorization
• 11.2. Strategy Mapping
• 11.3. Company Market Position/Share Analysis, 2025
• 11.4. Company Profiles/Listing
  • 11.4.1. Certara, USA.
    • 11.4.1.1. Company overview
    • 11.4.1.2. Financial performance
    • 11.4.1.3. Product benchmarking
    • 11.4.1.4. Strategic initiatives
  • 11.4.2. Dassault Systemes
    • 11.4.2.1. Company overview
    • 11.4.2.2. Financial performance
    • 11.4.2.3. Product benchmarking
    • 11.4.2.4. Strategic initiatives
  • 11.4.3. Advanced Chemistry Development, Inc. (now a part of Revvity )
    • 11.4.3.1. Company overview
    • 11.4.3.2. Financial performance
    • 11.4.3.3. Product benchmarking
    • 11.4.3.4. Strategic initiatives
  • 11.4.4. Simulations Plus
    • 11.4.4.1. Company overview
    • 11.4.4.2. Financial performance
    • 11.4.4.3. Product benchmarking
    • 11.4.4.4. Strategic initiatives
  • 11.4.5. Schrodinger, Inc.
    • 11.4.5.1. Company overview
    • 11.4.5.2. Financial performance
    • 11.4.5.3. Product benchmarking
    • 11.4.5.4. Strategic initiatives
  • 11.4.6. Chemical Computing Group ULC
    • 11.4.6.1. Company overview
    • 11.4.6.2. Financial performance
    • 11.4.6.3. Product benchmarking
    • 11.4.6.4. Strategic initiatives
  • 11.4.7. Physiomics Plc
    • 11.4.7.1. Company overview
    • 11.4.7.2. Financial performance
    • 11.4.7.3. Product benchmarking
    • 11.4.7.4. Strategic initiatives
  • 11.4.8. Rosa & Co. LLC
    • 11.4.8.1. Company overview
    • 11.4.8.2. Financial performance
    • 11.4.8.3. Product benchmarking
    • 11.4.8.4. Strategic initiatives
  • 11.4.9. BioSimulation Consulting Inc.
    • 11.4.9.1. Company overview
    • 11.4.9.2. Financial performance
    • 11.4.9.3. Product benchmarking
    • 11.4.9.4. Strategic initiatives
  • 11.4.10. Genedata AG
    • 11.4.10.1. Company overview
    • 11.4.10.2. Financial performance
    • 11.4.10.3. Product benchmarking
    • 11.4.10.4. Strategic initiatives
  • 11.4.11. Instem Group of Companies
    • 11.4.11.1. Company overview
    • 11.4.11.2. Financial performance
    • 11.4.11.3. Product benchmarking
    • 11.4.11.4. Strategic initiatives
  • 11.4.12. PPD, Inc. (Acquired by Thermo Fisher Scientific)11.4.13.1. Company overview
    • 11.4.12.1. Company overview
    • 11.4.12.2. Financial performance
    • 11.4.12.3. Product benchmarking
    • 11.4.12.4. Strategic initiatives
  • 11.4.13. Yokogawa Insilico Biotechnology GmbH
    • 11.4.13.1. Company overview
    • 11.4.13.2. Financial performance
    • 11.4.13.3. Product benchmarking
    • 11.4.13.4. Strategic initiatives